Core Insights - The company held a semi-annual performance briefing on September 3, 2025, where executives discussed the significance of the new product strategy as a key component of the "Three New and Two Transformations" strategy [1] - The company has established a new product business organization matrix centered around CSO, utilizing various methods such as exclusive agency, equity cooperation, buyout rights, and independent research and development to acquire new products with clinical value and market potential [1] Sales Performance - The total brand promotion business (CSO) has significantly advanced the introduction of new products and increased sales of existing products, achieving a sales scale of 9.591 billion yuan in the first half of the year [1] - The pharmaceutical manufacturing and OEM business has focused on creating a competitive product cluster, contributing to the implementation of the "new product" strategy, with sales revenue reaching 1.593 billion yuan, representing a year-on-year growth of 10.77% [1] Investment Initiatives - The company has established a new product strategy-related fund, "Wuhan Jiuying Venture Capital Fund Partnership (Limited Partnership)," which completed registration on January 7, 2025, with a fund size of 500 million yuan [1] - The investment focus of the fund is primarily on innovative drugs, high-end generic drugs, and other new products, aiming to actively introduce valuable domestic and international innovative drugs, modified new drugs, and high-end generic drugs [1]